Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing

Alumis updated its investor presentation highlighting envudeucitinib Phase 3 efficacy, upcoming SLE topline data and an expected NDA filing.Key Highlights:Original SEC Filing: ALUMIS INC. [ ALMS ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying im…

Alumis updated its investor presentation highlighting envudeucitinib Phase 3 efficacy, upcoming SLE topline data and an expected NDA filing.

Key Highlights:

Filed updated corporate deck as Exhibit 99.1 describing TYK2 programs and strategic plans.
Phase 3 ONWARD data: envudeucitinib showed leading PASI 100 and early PASI 90 responses with generally favorable safety through Week 24.
Topline Phase 2b LUMUS SLE results expected Q3 2026; potential pivotal readout for SLE opportunity.
NDA filing for envudeucitinib in moderate-to-severe plaque psoriasis anticipated Q4 2026.
A-005 CNS‑penetrant TYK2i: Phase 2 biomarker trial in Parkinson’s disease planned for 1H 2027.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.